Phase-Appropriate Service For cGMP Plasmid DNA Manufacturing

The growing number of cell and gene therapy products advancing toward commercialization is increasing demand for plasmid DNA, a critical input for the development and manufacturing of many advanced therapies. Incorporating cGMP quality materials early in the development process is essential to mitigate risk of raw material changes downstream and ease the burden of CMC filings.

Thermo Fisher Scientific now offers phase-appropriate service, which includes access to full cGMP quality plasmid material regardless of clinical phase of development. Discover the benefits of utilizing plasmid produced with full application of cGMP practices compared to “GMP-like” plasmids.